Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2026.069227
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

COMMENTARY

Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial

Leenah Abdulgader1, Abdullah Esmail2,*
1 Department of Surgery, University of Maryland Medical Center, Baltimore, MD, USA
2 Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA
* Corresponding Author: Abdullah Esmail. Email: email
(This article belongs to the Special Issue: Molecular Targets and Combinatorial Therapeutics of Liver Cancer)

Oncology Research https://doi.org/10.32604/or.2026.069227

Received 18 June 2025; Accepted 08 January 2026; Published online 28 January 2026

Abstract

Unresectable hepatocellular carcinoma (HCC) remains a global challenge, with limited effective treatment options for advanced-stage disease. The HIMALAYA trial (phase III randomized study that evaluated the STRIDE regimen) introduced the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen, an immunotherapy-based approach that achieved a median overall survival (OS) of 16.43 months compared to 13.77 months with sorafenib. While statistically significant, this ~2.7 months OS gain warrants scrutiny in light of STRIDE’s increased immune-related toxicity and cost. This commentary evaluates STRIDE’s impact within the broader landscape of first-line systemic therapy for unresectable HCC, alongside other regimens such as atezolizumab plus bevacizumab and nivolumab plus ipilimumab. We explore STRIDE’s mechanism of action, safety profile, modest progression-free survival (PFS) improvement, and implementation challenges, incorporating insights from 2023–2025 research. In addition, we discussed its limitations in non-viral HCC and Child-Pugh B patients, the role of emerging biomarkers, and the potential of radiation to enhance immunotherapy efficacy. As a dual immune checkpoint inhibitor (ICI) strategy, STRIDE offers an important advance that may not only extend survival but also open the door to future curative approaches. However, optimizing its use will require refined patient selection and further investigation of synergistic combination therapies.

Keywords

Hepatocellular carcinoma (HCC); single tremelimumab regular interval durvalumab (STRIDE) regimen; HIMALAYA trial; overall survival; systemic therapy

  • 19

    View

  • 3

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link